Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 8/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6155345 | 0.87 | CYP3A4 (0.49) | TSHRALDH1A1 | |
| SCHEMBL6154584 | 0.86 | MEN1 (0.51) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL4871795 | 0.84 | MAPK1 (0.45) | TSHR | |
| SCHEMBL4866714 | 0.81 | RBP4 (0.36) | MAPTALDH1A1 | |
| SCHEMBL6153877 | 0.76 | KDM1A (0.41) | TSHR | |
| SCHEMBL7379940 | 0.76 | SIGMAR1 (0.41) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL11831680 | 0.74 | AVPR1A (0.60) | APP | |
| SCHEMBL7674584 | 0.74 | APP (0.52) | APPL3MBTL1PSEN1PSEN2APH1B | |
| SCHEMBL6155641 | 0.73 | AVPR1A (0.52) | APPL3MBTL1PSEN1PSEN2APH1B | |
| SCHEMBL1295044 | 0.73 | ALDH1A1 (0.64) | L3MBTL1LMNAGAASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7396930-B2 | making spiro(benzo(c)thiophene-1 (3H),4'-piperidine) derivatives; involves reacting a mercapto compound with a 2-halophenylalkyl halide, reacting with an alkyllithium, then N-ethoxycarbonyl-4-piperidone, dehydration and cyclization; industrial scale; novel intermediates to neurokinin receptor antagonist | SANKYO COMPANY, LIMITED (JP) | 2008-07-08 | — | — | US | disclosed |
| US-20050209262-A1 | Process for producing optically active sulfoxide | SANKYO COMPANY, LIMITED (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1557420-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SULFOXIDE | Sankyo Company, Limited (JP) | 2005-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209262-A1 | Process for producing optically active sulfoxide | TST, TMT1A, PPOX | APP 1937/4885L3MBTL1 1254/4885PSEN1 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.